SCHEMBL7962647

SCHEMBL7962647

COC(=O)C(c1ccccc1)n1nc(Cc2cccc3ccccc23)c2ccccc2c1=O

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 9/20 0.78
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ P2RX3 P56373 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ SRC P12931 2/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ HCK P08631 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7960570 0.88 CMA1 (1.00) CMA1SMN1; SMN2POLBP2RX3SRC
SCHEMBL7966175 0.82 CMA1 (0.81) CMA1POLBLMNAHPGDKDM4E
SCHEMBL18900937 0.82 CMA1 (0.73) CMA1SMN1; SMN2POLBP2RX3SRC
SCHEMBL7961042 0.81 CMA1 (0.83) CMA1POLB
SCHEMBL1851671 0.77 CMA1 (1.00) CMA1SMN1; SMN2POLBP2RX3SRC
SCHEMBL1849731 0.77 CMA1 (0.79) CMA1SMN1; SMN2POLBP2RX3LMNA
SCHEMBL6115028 0.73 CMA1 (1.00) CMA1LMNAHPGDCYP1A2CYP3A4
SCHEMBL6115031 0.73 CMA1 (0.61) CMA1SMN1; SMN2P2RX3LMNAHPGD
SCHEMBL1851876 0.73 CMA1 (0.83) CMA1SMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL7963507 0.72 CMA1 (0.73) CMA1SMN1; SMN2LMNAHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323991-B1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-05-31 — — EP disclosed
US-8969348-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-03 — — US disclosed
US-8969348-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-03 — — US disclosed
US-20120129863-A1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 — — US disclosed
US-20120129863-A1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 — — US disclosed
WO-2010019417-A2 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129863-A1 CHYMASE INHIBITORS CMA1, CPA3, SERPINB1 CMA1 1/4885SMN1; SMN2 1912/4885POLB 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback